You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Platinum-based chemotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Gynecologic Cancer Trial (Experimental product - Fortifit® Powder, Standard of care)

Not yet recruiting
  • Gynecologic Cancer
  • Experimental product - Fortifit® Powder
  • Standard of care
  • (no location specified)
Oct 14, 2023

NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • (no location specified)
Aug 17, 2023

Cancer, Ototoxicity, Drug-Induced, Quality of Life Trial (Patients suffering from chemo-induced ototoxicity)

Not yet recruiting
  • Cancer
  • +3 more
  • Patients suffering from chemotherapy-induced ototoxicity
  • (no location specified)
Jun 29, 2023

Non Small Cell Lung Cancer, Propranolol Trial (Propranolol HCl, Sintilimab, Chemotherapy)

Not yet recruiting
  • Non Small Cell Lung Cancer
  • Propranolol
  • Propranolol hydrochloride
  • +2 more
  • (no location specified)
Jul 31, 2023

Cervical Cancer Trial in Wuhan (Recombinant humanized anti-PD-1 mAb injection, Cisplatin, Bevacizumab Injection)

Not yet recruiting
  • Cervical Cancer
  • Recombinant humanized anti-PD-1 monoclonal antibody injection
  • +4 more
  • Wuhan, Hubei, China
    Tongji Hospital affiliated to Tongji Medical College of Huazhong
Nov 3, 2023

NSCLC Trial in Worldwide (RO7247669, Pembrolizumab, Paclitaxel)

Recruiting
  • Non-small Cell Lung Cancer
  • Benowa, Queensland, Australia
  • +6 more
Mar 16, 2023

Cervical Cancer Trial in Chongqing, Fuzhou (TQB2868 injection, Paclitaxel injection, Cisplatin injection)

Not yet recruiting
  • Cervical Cancer
  • TQB2868 injection
  • +4 more
  • Chongqing, Chongqing, China
  • +1 more
Aug 17, 2023

Lazertinib as the 2nd-Line Treatment in EGFR Mutation+ NSCLC

Completed
  • Non-small Cell Lung Cancer
  • (no location specified)
May 8, 2023

Metastatic Cervical Cancer Trial (Tislelizumab, Sitravatinib)

Not yet recruiting
  • Metastatic Cervical Cancer
  • (no location specified)
Jan 31, 2023

Chemotherapeutic Toxicity Trial (Home Based Walking Program)

Not yet recruiting
  • Chemotherapeutic Toxicity
  • Home Based Walking Program
  • (no location specified)
Aug 28, 2023

NSCLC Trial (Durvalumab)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • (no location specified)
Jun 22, 2023

Small Cell Lung Cancer, SCLC, Extensive Stage Small Cell Lung Cancer Trial (Durvalumab, Monalizumab, Carboplatin or Cisplatin)

Not yet recruiting
  • Small Cell Lung Cancer
  • +2 more
  • (no location specified)
Jun 5, 2023

Lung Adenocarcinoma, Stage IV NSCLC, PD-1 Inhibitor Trial (Serplulimab and Bevacizumab injection)

Not yet recruiting
  • Lung Adenocarcinoma
  • +3 more
  • Serplulimab and Bevacizumab injection
  • (no location specified)
Dec 21, 2022

NSCLC Stage IV Trial in Gauting (combination regimen tremelimumab /durvalumab, platinum-based chemo (SoC))

Withdrawn
  • NSCLC Stage IV
  • combination regimen tremelimumab /durvalumab
  • platinum-based chemotherapy (SoC)
  • Gauting, Germany
    Asklepios Fachkliniken München-Gauting
Sep 26, 2022

Toripalimab, First-line Treatment Trial in Guangzhou (EP/EC+PD-1)

Recruiting
  • Toripalimab
  • First-line Treatment
  • Guangzhou, Guangdong, China
    Sun Yat-sen University cancer center
Mar 7, 2023

Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Urothelial Carcinoma Trial in Darlinghurst, Kogarah,

Terminated
  • Advanced Solid Tumor
  • +3 more
  • Darlinghurst, New South Wales, Australia
  • +1 more
Dec 18, 2022

Non-squamous Non-small-cell Lung Cancer Trial in Hangzhou (Tusamitamab ravtansine+Sintilimab+Carboplatin or

Not yet recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 5, 2023

NSCLC Trial in Tianjing (Envalfolimab subcutaneously injected+Platinum-based doublet chemo intravenous injection,

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
  • placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection
  • Tianjing, Tianjin, China
    Tianjin cancer hospital
Nov 3, 2023

High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1

Suspended
  • NSCLC Stage IV
  • NSCLC, Stage IIIC
  • Primary Immune Response (PIR) test by Biodesix, Inc.
  • San Carlos, California
  • +1 more
Jan 26, 2023

NSCLC Trial (HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin)

Not yet recruiting
  • Non-Small Cell Lung Cancer
  • HS-10241+ Almonertinib
  • Pemetrexed + Cisplatin /Carboplatin
  • (no location specified)
Oct 29, 2023

Endometrial Cancer Trial (MK-2870, Doxorubicin, Paclitaxel)

Not yet recruiting
  • Endometrial Cancer
  • MK-2870
  • +2 more
  • (no location specified)
Nov 10, 2023

Advanced or Metastatic NSCLC Trial in Moscow, Saint Petersburg, St. Petersburg (Ceralasertib, Durvalumab)

Recruiting
  • Advanced or Metastatic NSCLC
  • Moscow, Russian Federation
  • +7 more
Jul 4, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (BL-B01D1, capecitabine, gemcitabine)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 31, 2023

Triple Negative Breast Cancer Trial in Dhaka (Doxorubicin, Cyclophosphamide, Paclitaxel)

Not yet recruiting
  • Triple Negative Breast Cancer
  • Dhaka, Bangladesh
    Bangabandhu Sheikh Mujib Medical University
May 24, 2023

Cholangiocarcinoma Trial in Birmingham (Novel combination of chemo and immunotherapy)

Recruiting
  • Cholangiocarcinoma
  • Novel combination of chemotherapy and immunotherapy
  • Birmingham, Alabama
    University of Alabama at Birmingham
Jul 28, 2022